Myotec Therapeutics Completes Merger with Hybrid BioSystems to Form PsiOxus Therapeutics

LONDON--(BUSINESS WIRE)--Myotec Therapeutics, Ltd. (Myotec) and Hybrid BioSystems, Ltd. (Hybrid) today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets. This pipeline will be supported with an additional financing round of £3.6 million ($5.8 million), led by Imperial Innovations and with participation from all of the major investors from both of the merged predecessor companies.

Back to news